Prognia
Drug Database
🇪🇺EU · EMAAuthorisedATC: B03XA05

Evrenzo(roxadustat)

Anemia;Kidney Failure, Chronic

Marketing Authorisation Holder: Astellas Pharma Europe B.V.

EMA Authorisation: 18/08/2021

INN: roxadustat

Indication

Evrenzo is indicated for treatment of adult patients with symptomatic anaemia associated with chronic kidney disease (CKD).

Official EMA Resources

View on EMA (ema.europa.eu)

AI Drug & Interaction Analysis

Free account required

Ask Prognia AI about Evrenzo — dosing recommendations, drug interactions, and current guideline evidence from ESC, EMA, NICE and more.

Medical disclaimer: This information is intended for qualified healthcare professionals. Always verify with the official EMA Summary of Product Characteristics (SmPC) before clinical use.